Dr. McLane's research groups
                            2004-2005                                                2005-2006
 

                                          2006-2007
                       

2004-2005: front row: Claire Zelinskas ('05), Jing Tian (PhD graduate student), Apoorva Srivastava ('05), back row: Xiaoming Zhang (research specialist), Carrie Paquette-Straub (research associate, along with her soon-to-be born Rachel!), Dr. McLane, Bryn Werbos ('05)

2005-2006: front row: as in 2004-2005, with the addition of Dara Missan ('06, back row, far right) and Brett Hensley ('07, front far right). Collaborator Dr. Mary Beth Miele is next to Dr. McLane in the front row.

2006-2007: Stephanie DiRosato ('08), Carrie Paquette-Straub, Dr. McLane,  Jing Tian

Cancer metastasis is the major obstacle to cancer cure. Melanoma is one of the most rapidly increasing types of cancer, and malignant melanoma is particularly aggressive in its ability to metastasize and the lack of any successful treatment. In 1990, I started working with a group of naturally occurring protein from viper venom, called  DISINTEGRINS. Some of these proteins can be injected into a mouse along with melanoma cells and prevent the tumor cells from forming new colonies within the lungs.

The snake pictured above is Eristocophis macmahoni, which originates from the deserts of southwestern Asian, and which produces a very unique disintegrin, called eristostatin. This disintegrin can inhibit melanoma cell lung colonization in a mouse model. The mechanism by which it accomplishes this is still unknown. My research is looking into the motifs within eristostatin's sequence which gives it the ability to have this anti-cancer property. Undergraduate students (Alice Wong '03, Melissa Kuchar '01) in my lab have described the receptors found on the surface of four different types of melanoma cells¹, and the effect of using mutated forms of eristostatin in interactions with those melanoma cells². Claire Zelinskas ('05) and Apoorva Srivastava ('05)  created a series of alanine mutations within eristostatin's sequence and expressed these mutations as recombinant fusion proteins. Bryn Werbo ('05)sinvestigated how we can improve the recombinant protein yield by purifying inclusion bodies.  Jing Tian's graduate studies are focusing on characterizing the recombinant proteins' interactions with 1205-LU, C8161, M24met and MV3 melanoma cells using confocal microscopy, flow cytometry and in vivo hematogenous metastasis. In addition, she isl investigating whether eristostatin is able to make the melanoma cells better targets for natural killer cells in vivo.

Brett Hensley ('07)  did the first studies ever on intracellular signalling within melanoma cells following eristostatin exposure. Dara Missan ('06) studied how melanoma cells can vary in their metastatic potential as well as their tumor suppressor and tumor promoter gene expression.

Stephanie DiRosato ('08) studyied how five groups of melanoma cells have their intracellular phosphorylation change when incubated with eristostatin.

Mollie Kostielney ('09) did cytotoxicity assays using NK cells and six types of melanoma cells. Alaa Mahmoud ('10) has continued those experiments with a flow cytometric method. Liana Sherrod ('10) did the first ever adhesion exepriments with atomic force microscopy.

--------------------------------------------------------
¹Effect of the disintegrin eristostatin on hematogenous metastasis in three models of human malignant melanoma. Poster #5911, Proceedings of the American Association for Cancer Research 44: 1180, 2003.
² McLane MA, Kuchar, MA, Brando C, Santoli D, Paquette-Straub CA, Miele ME. New insights on disintegrin-receptor interactions: Eristostatin and melanoma cells, Haemostasis 31: 3-6, 177-182, 2001.

Medical Technology department homepage